Botox for Frown Lines: Onset & Duration Vary
- A recent study published in JAMA Dermatology investigated teh effectiveness of four different botulinum toxin A (BoNT/A) formulations in treating glabellar lines, commonly known as frown lines.
- Lemdani,BA,of the University of Pennsylvania,involved 143 women aged 30-65.
- The research indicated that ABoNT/A and PBoNT/A had a quicker onset of action compared to OBoNT/A and IBoNT/A. Specifically, ABoNT/A (67.4%) and PBoNT/A (61.7%) showed considerably faster strain...
Discover surprising insights into Botox injections! A recent clinical trial comparing four botulinum toxin A formulations for frown lines revealed meaningful differences.Researchers found that ABoNT/A and PBoNT/A showed a quicker onset than OBoNT/A and IBoNT/A,while PBoNT/A displayed a greater effect at three months. Teh study, published in JAMA Dermatology, involving 143 women, assessed glabellar strain and patient satisfaction. Maximum efficacy for wrinkle treatments occurred around day 30 for all formulations. News Directory 3 is following the breakthroughs in dermatological science. Uncover which Botox formulation might potentially be best for you. Discover what’s next in individualized treatment strategies.
Botox Injection Study Shows Differences Among formulations
Updated May 28, 2025
A recent study published in JAMA Dermatology investigated teh effectiveness of four different botulinum toxin A (BoNT/A) formulations in treating glabellar lines, commonly known as frown lines. The randomized clinical trial revealed quantitative differences in onset and duration among the formulations, offering insights for individualized treatment approaches using Botox injections.
The study, led by Mehdi S. Lemdani,BA,of the University of Pennsylvania,involved 143 women aged 30-65. Participants were divided into four groups, each receiving a different BoNT/A formulation: onabotulinum toxin A (OBoNT/A), abobotulinum toxin A (ABoNT/A), prabotulinum toxin A (PBoNT/A), or incobotulinum toxin A (IBoNT/A). researchers then monitored the women for six months, assessing glabellar strain using dynamic three-dimensional photogrammetry and patient satisfaction via FACE-Q surveys.
The research indicated that ABoNT/A and PBoNT/A had a quicker onset of action compared to OBoNT/A and IBoNT/A. Specifically, ABoNT/A (67.4%) and PBoNT/A (61.7%) showed considerably faster strain reduction at day 3 compared to OBoNT/A (48.0%) and IBoNT/A (40.3%). Furthermore, PBoNT/A maintained a significantly higher strain reduction (20.5%) than OBoNT/A (0.5%) at day 180.
Maximum treatment efficacy for each Botox injection type typically occurred around day 30, with an overall median efficacy of 88% across the entire group. The study also found that greater initial glabellar line severity correlated with more meaningful betterment across all formulations. Patient satisfaction, as measured by FACE-Q scores, improved significantly across all groups by day 30, with these improvements generally lasting for the entire six-month study period. Notably, no adverse events were reported during the trial.
“This randomized clinical trial demonstrated precise quantitative differences between 4 BoNT/A formulations in treating glabellar strain,” the study authors wrote.
The authors suggest that quantifying the effect of each BoNT/A formulation “provides an objective foundation to guide individualized product selection and patient education” regarding Botox injections.
What’s next
Future research could explore differential dosing,treatment of adjoining regions,and include male participants to broaden the applicability of these findings regarding Botox injections and other botulinum toxin treatments.